The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands.

Despite advances in preventive therapy, prognosis in chronic kidney disease (CKD) is still grim. Clinical cohorts of CKD patients provide a strategic resource to identify factors that drive progression in the context of clinical care and to provide a basis for improvement of outcome. The combination with biobanking, moreover, provides a resource for fundamental and translational studies. In 2007, the Dutch government initiated and funded the String of Pearls Initiative (PSI), a strategic effort to establish infrastructure for disease-based biobanking in the University Medical Centres (UMCs) in the Netherlands, in a 4-year start-up period. CKD was among the conditions selected for biobanking, and this resulted in the establishment of the Biobank of Nephrological Diseases-NL (BIND-NL) cohort. Patients with CKD Stages 1-4 are eligible. The data architecture is designed to reflect routine care, with specific issues added for enrichment, e.g. questionnaires. Thus, the collected clinical and biochemical data are those required by prevailing guidelines for routine nephrology care, with a minimal dataset for all patients, and diagnosis-specific data for the diagnostic categories of primary and secondary glomerular disorders and adult dominant polycystic kidney disease, respectively. The dataset is supplemented by a biobank, containing serum, plasma, urine and DNA. The cohort will be longitudinally monitored, with yearly follow-up for clinical outcome. Future linking of the data to those from the national registries for renal replacement therapy is foreseen to follow the patients' lifeline throughout the different phases of renal disease and different treatment modalities. In the design of the data architecture, care was taken to ensure future exchangeability of data with other CKD cohorts by applying the data harmonization format of the Renal DataSHaPER, with a dataset based upon standardized indicator sets to facilitate collaboration with other CKD cohorts. Enrolment started in 2010, and over 2200 eligible patients have been enrolled in the different UMCs. Follow-up of enrolled patients has started, and enrolment will continue at a slower rate. The aggregation and standardization of clinical data and biosamples from large numbers of CKD patients will be a strategic resource not only for clinical and translational research, but also by its basis in routine clinical care for clinical governance and quality improvement projects.

[1]  P. Ruggenetu Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .

[2]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[3]  P. Peeters,et al.  Analysis and interpretation of cost data in dialysis: review of Western European literature. , 2000, Health policy.

[4]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[5]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .

[6]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[7]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[8]  M. Bots,et al.  Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. , 2005, Journal of nephrology.

[9]  G. Eknoyan,et al.  Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[10]  M. Bots,et al.  Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232] , 2006, Trials.

[11]  Translating knowledge of the human genome into clinical practice in nephrology dialysis and transplantation: the renal genome network (ReGeNet). , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Ronald P. Stolk,et al.  Universal risk factors for multifactorial diseases-LifeLines : a three-generation population-based study , 2008 .

[13]  Olivier Moranne,et al.  Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[14]  Y. Ohashi,et al.  Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function , 2010, Clinical and Experimental Nephrology.

[15]  Mark N. Wass,et al.  Genetic loci influencing kidney function and chronic kidney disease , 2010, Nature Genetics.

[16]  R. Garrick Timing of Onset of CKD-Related Metabolic Complications , 2010 .

[17]  A. Köttgen Genome-wide association studies in nephrology research. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  Hans Hillege,et al.  Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies , 2010, International journal of epidemiology.

[19]  G. Remuzzi,et al.  Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. , 2011, Journal of the American Society of Nephrology : JASN.

[20]  Hans-Ulrich Prokosch,et al.  The German Chronic Kidney Disease (GCKD) study: design and methods. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[22]  J. Luther Sodium intake, ACE inhibition, and progression to ESRD. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[24]  Raymond Vanholder,et al.  Implementation of proteomic biomarkers: making it work , 2012, European journal of clinical investigation.

[25]  Beverley Matthews,et al.  Estimating the financial cost of chronic kidney disease to the NHS in England , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  Marcello Tonelli,et al.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.

[27]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword , 2013 .